Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
Submitted by susan on Wed, 2017-10-11 10:35
The rVSVΔG-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 × 107 plaque-forming units (PFU) in a trial in Guinea. This study provides further safety and immunogenicity data.
Main Topic:
Attachment(s):
Mark Content Private(Internal):
Email Alert:
1-26
Publication Date:
06/10/2017